ICAM1 and pancreatic neoplasm: In pancreatic tumour tissues, PAK4KO did not change the ICAM-1 (Figure 4a) or VCAM-1 (Figure 4b) expression in the absence of gemcitabine, nor did it affect vascular normalisation, as shown by the unchanged NG2/CD31 (Figure 4c) and α-SMA/CD31 (Figure 4d) ratios.